Hagan Joseph P 4
4 · Regulus Therapeutics Inc. · Filed Jan 31, 2025
Insider Transaction Report
Form 4
Hagan Joseph P
DirectorChief Executive Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-01-30+1,350,000→ 1,350,000 totalExercise: $1.00Exp: 2035-01-29→ Common Stock (1,350,000 underlying) - Purchase
Common Stock
2025-01-30$1.09/sh+50,000$54,260→ 260,808 total
Footnotes (2)
- [F1]The weighted average purchase price for the transaction reported was $1.0852, and the range of prices were between $1.065 and $1.0897. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each price will be provided.
- [F2]The stock option commenced vesting on January 1, 2025 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.